Dexcom and ŌURA Announce Strategic Partnership
Dexcom (NASDAQ:DXCM) and ŌURA have announced a strategic partnership to integrate Dexcom's glucose biosensor data with ŌURA's health metrics. The partnership includes a $75 million strategic investment from Dexcom in ŌURA's Series D funding, valuing ŌURA at over $5 billion. The companies will enable two-way data flow between their products and launch co-marketing efforts.
The first app integration is expected in the first half of 2025. ŌURA reported selling 2.5 million rings and expects to double annual sales to approximately $500 million in 2024. The partnership aims to provide users with comprehensive metabolic health management by combining glucose data with sleep, stress, heart health, and activity metrics.
Dexcom (NASDAQ:DXCM) e ŌURA hanno annunciato una partnership strategica per integrare i dati del biosensore della glicemia di Dexcom con le metriche di salute di ŌURA. La partnership include un investimento strategico di 75 milioni di dollari da parte di Dexcom nel finanziamento di Serie D di ŌURA, valutando ŌURA a oltre 5 miliardi di dollari. Le aziende abiliteranno un flusso bidirezionale di dati tra i loro prodotti e avvieranno sforzi di co-marketing.
La prima integrazione dell'app è prevista nella prima metà del 2025. ŌURA ha riportato di aver venduto 2,5 milioni di anelli e si aspetta di raddoppiare le vendite annuali a circa 500 milioni di dollari nel 2024. La partnership mira a fornire agli utenti una gestione completa della salute metabolica combinando i dati della glicemia con le metriche di sonno, stress, salute del cuore e attività fisica.
Dexcom (NASDAQ:DXCM) y ŌURA han anunciado una asociación estratégica para integrar los datos del biosensor de glucosa de Dexcom con las métricas de salud de ŌURA. La asociación incluye una inversión estratégica de 75 millones de dólares por parte de Dexcom en la financiación de la Serie D de ŌURA, valorando a ŌURA en más de 5 mil millones de dólares. Las empresas permitirán un flujo de datos bidireccional entre sus productos y lanzarán esfuerzos de co-marketing.
Se espera que la primera integración de la aplicación ocurra en la primera mitad de 2025. ŌURA informó haber vendido 2,5 millones de anillos y espera duplicar las ventas anuales a aproximadamente 500 millones de dólares en 2024. La asociación tiene como objetivo proporcionar a los usuarios una gestión integral de la salud metabólica al combinar los datos de glucosa con las métricas de sueño, estrés, salud del corazón y actividad.
Dexcom (NASDAQ:DXCM)과 ŌURA는 Dexcom의 혈당 바이오센서 데이터를 ŌURA의 건강 지표와 통합하기 위한 전략적 파트너십을 발표했습니다. 이 파트너십에는 Dexcom이 ŌURA의 시리즈 D 자금에 7500만 달러의 전략적 투자를 포함하여 ŌURA의 가치를 50억 달러 이상으로 평가합니다. 두 회사는 제품 간의 양방향 데이터 흐름을 가능하게 하고 공동 마케팅 노력을 시작할 것입니다.
첫 번째 앱 통합은 2025년 상반기에 예상됩니다. ŌURA는 250만 개의 링을 판매했다고 보고하며 2024년에는 연간 판매를 약 5억 달러로 두 배로 늘릴 것으로 예상하고 있습니다. 이 파트너십은 혈당 데이터와 수면, 스트레스, 심장 건강 및 활동 지표를 결합하여 사용자에게 포괄적인 대사 건강 관리를 제공하는 것을 목표로 합니다.
Dexcom (NASDAQ:DXCM) et ŌURA ont annoncé un partenariat stratégique visant à intégrer les données du biosenseur de glucose de Dexcom avec les indicateurs de santé d'ŌURA. Ce partenariat comprend un investissement stratégique de 75 millions de dollars de Dexcom dans le financement de Série D d'ŌURA, valorisant ŌURA à plus de 5 milliards de dollars. Les entreprises permettront un flux de données bidirectionnel entre leurs produits et lanceront des efforts de co-marketing.
La première intégration de l'application est attendue dans la première moitié de 2025. ŌURA a rapporté avoir vendu 2,5 millions d'anneaux et s'attend à doubler ses ventes annuelles à environ 500 millions de dollars en 2024. Ce partenariat vise à offrir aux utilisateurs une gestion globale de la santé métabolique en combinant les données de glucose avec les indicateurs de sommeil, de stress, de santé cardiaque et d'activité physique.
Dexcom (NASDAQ:DXCM) und ŌURA haben eine strategische Partnerschaft angekündigt, um die Daten des Blutzucker-Biosensors von Dexcom mit den Gesundheitsmetriken von ŌURA zu integrieren. Die Partnerschaft beinhaltet eine strategische Investition von 75 Millionen Dollar von Dexcom in das Series D-Finanzierungsrunde von ŌURA, die ŌURA auf über 5 Milliarden Dollar bewertet. Die Unternehmen werden einen bidirektionalen Datenaustausch zwischen ihren Produkten ermöglichen und gemeinsame Marketingmaßnahmen starten.
Die erste App-Integration wird in der ersten Hälfte des Jahres 2025 erwartet. ŌURA berichtete von einem Verkauf von 2,5 Millionen Ringen und erwartet, die jährlichen Verkäufe im Jahr 2024 auf etwa 500 Millionen Dollar zu verdoppeln. Die Partnerschaft zielt darauf ab, den Nutzern ein umfassendes Management der metabolischen Gesundheit zu bieten, indem Blutzucker-Data mit Schlaf-, Stress-, Herzgesundheits- und Aktivitätsmetriken kombiniert wird.
- Strategic investment of $75M in ŌURA, showing strong financial commitment
- Expected revenue doubling for ŌURA to $500M in 2024
- Expansion into metabolic health market through product integration
- Access to larger customer base through co-marketing efforts
- Integration launch delayed until first half of 2025
Insights
The strategic partnership between Dexcom and ŌURA represents a significant market opportunity in the growing digital health sector. The
The integration of glucose monitoring with sleep and activity tracking addresses a massive market, considering
The integration of Dexcom's glucose biosensors with ŌURA's comprehensive biometric tracking creates a powerful synergy in metabolic health monitoring. This partnership represents a significant advancement in consumer health technology by combining medical-grade glucose monitoring with continuous lifestyle metrics. The integration, launching in 2025, will provide unprecedented insights into how daily behaviors affect glucose levels.
With
- Partnership will enable two-way data flow between Dexcom glucose biosensors and apps and Oura Ring and the Oura App, providing a first-of-its-kind metabolic health management experience
- Co-marketing efforts will help ŌURA and Dexcom reach millions of new users seeking better metabolic health
-
Dexcom is investing
$75 million
Dexcom and ŌURA announce a strategic partnership to help millions of people improve their metabolic health through the integration of Dexcom glucose data with vital sign, sleep, stress, heart health and activity data from Oura Ring. (Photo: Business Wire)
“Dexcom offers the most accurate glucose biosensing systems on the market that help reveal the impact of daily lifestyle choices on glucose levels and enable our users to make informed decisions about their health and overall well-being,” said Matt Dolan, executive vice president of strategy and corporate development at Dexcom. “Partnering with ŌURA gives us the opportunity to redefine the category again, integrating data from Dexcom glucose biosensors with the continuous insights and metrics measured by Oura Ring. This powerful combination will attract new shared customers who want to better understand the link between activity, sleep, nutrition and their glucose.”
With this partnership, Dexcom and ŌURA will launch integrations enabling data to flow between Dexcom and ŌURA products, including Dexcom glucose biosensors, Dexcom apps, Oura Ring and the Oura App, so shared users can track their glucose levels and understand the impact of behaviors and biology on their metabolic health. The companies will also co-market and cross-sell each other’s products. The first app integration resulting from the partnership is expected to launch in the first half of 2025.
“Ninety-seven percent of Oura Members have expressed interest in understanding how the food they eat impacts their health,” said Tom Hale, ŌURA chief executive officer. “This partnership with Dexcom will enable us to empower our members to make informed decisions and adjust behaviors to positively impact their biometrics and long-term health. Working together, ŌURA and Dexcom will help members decide what and when to eat by surfacing correlations between activities like sleep and exercise and members’ glucose levels. And because we know that people are affected differently by the same foods and activities, guidance and insights will be personalized.”
Dexcom has been the pioneer in glucose biosensing for 25 years, with a long list of first-in-market innovations. Most recently, Dexcom led the creation of a new category by launching Stelo, the first glucose biosensor cleared for use without a prescription1 in the
This year has marked a significant acceleration of ŌURA’s business, including its metabolic health roadmap. Earlier this year, ŌURA announced that it has sold 2.5 million rings, expects to see annual sales double in 2024 to roughly
Eighty-eight percent of Americans are not in optimal metabolic health,2 which comes with increased risk of developing co-morbid conditions like diabetes, heart disease, stroke or all three.3 Strategic partnerships that combine medical-grade technology with advanced software are driving forward the consumerization of healthcare, allowing consumers to drive their health journeys and empowering them with their own health information. Dexcom and ŌURA plan to meet a need that will change the healthcare landscape going forward.
About Dexcom
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
Dexcom. Discover what you’re made of. For more information, visit Dexcom.com.
About ŌURA
ŌURA delivers personalized health data, insights, and daily guidance with Oura Ring, the leading smart ring that helps you live healthier, longer. Guided by a mission of changing the healthcare paradigm from sick care to preventative health, ŌURA makes wellness and recovery a daily practice through sleep, activity, readiness, stress, resilience, women’s health and heart health. Millions of Oura Members around the world use Oura Ring as a personalized health companion that meets them where they are.
Validated against medical gold standards and driven by continuous monitoring of 50+ individual health and wellness biometrics and insights, the lightweight and comfortable Oura Ring is building the most scientifically validated wearable. Thousands of teams, research organizations and concierge medical practices manage the health of their populations with ŌURA, and its ecosystem includes 800+ partners across women’s health, metabolic health, fitness, behavioral health and more. In 2013, ŌURA was founded in
Oura Ring is not a medical device and is not intended to diagnose, treat, cure, monitor or prevent medical conditions/illnesses.
1Stelo User Guide.
2https://www.liebertpub.com/doi/10.1089/met.2018.0105.
3https://www.hopkinsmedicine.org/health/conditions-and-diseases/metabolic-syndrome.
Category: IR
View source version on businesswire.com: https://www.businesswire.com/news/home/20241119063628/en/
Dexcom Media Contact
James McIntosh
959-716-6698
mediarelations@dexcom.com
Dexcom Investor Contact
Sean Christensen
858-203-6657
investor-relations@dexcom.com
ŌURA Media Contact
Kate Brinks
415-823-3121
press@ouraring.com
Source: DexCom, Inc.
FAQ
When will Dexcom and ŌURA launch their first integrated app?
How much did Dexcom (DXCM) invest in ŌURA's Series D funding?
What is the current valuation of ŌURA after Dexcom's (DXCM) investment?
What are ŌURA's projected sales for 2024 after partnering with Dexcom (DXCM)?
